5 Key Takeaways

• 1

  Australia experiences approximately 250,000 hospital admissions annually due to medication toxicities, costing over a billion dollars.

• 2

  The RCPA advocates for pharmacogenetic testing to prevent medication-related hospitalizations but acknowledges existing barriers to implementation.

• 3

  Limited access to pharmacogenomic testing in Australia is primarily due to lack of coverage under the Medicare Benefits Schedule.

• 4

  The RCPA recommends expanded public funding, improved education for patients and clinicians, and targeted research to enhance pharmacogenomic testing accessibility.

• 5

  National trials are being conducted to evaluate the benefits of pharmacogenomic-guided prescribing, including studies on antidepressants.